首页> 外文OA文献 >LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

【2h】

LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

机译：LBA4 Gemstone-302：具有安慰剂或CS1001的铂类化疗（Chemo）的III期研究，抗PDL1抗体，用于一线（1L）先进的非小细胞肺癌（NSCLC）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
C. Zhou; Z. Wang; Y. Sun; L. Cao; Z. Ma; R. Wu; Y. Yu; W. Yao; J. Chang; J. Chen; W. Zhuang; J. Cui; X. Chen; Y. Lu; H. Shen; P. Li; J. Wang; B. Sun; D. Lu; J. Yang;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. AvaALL: Open-Label Randomized Phase 1Mb Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Continuous Bevacizumab (BV) Treatment Beyond Disease Progression in Patients (pts) With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) After First-Line (1L) Treatment With BV Plus Platinum-Doublet Chemotherapy (CT) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla11期

机译：AvaALL：开放标签随机1Mb临床试验，评估在初次手术后晚期非鳞状非小细胞肺癌（NSCLC）患者病情进展之外，是否进行持续贝伐单抗（BV）治疗的标准治疗的有效性和安全性BV加上铂金双线化疗（CT）的线（1L）治疗
2. Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC) [J] . Hirsch F. R., Govindan R., Zvirbule Z., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：来自Onartuzumab联合一线铂-双线化疗在晚期鳞状细胞非小细胞肺癌（sq NSCLC）的第2期安慰剂对照研究中的疗效和安全性结果
3. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) [J] . Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第3期

机译：贝伐单抗和厄洛替尼（BE）一线治疗晚期非鳞状非小细胞肺癌（NSCLC）（IIIB / IV期），然后在疾病进展时进行铂类化疗（CT）：一项多中心II期试验（ SAKK 19/05）
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized Double-Blind Placebo-Controlled Phase III Study—CALGB 30607 (Alliance) [O] . Maria Q. Baggstrom, Mark A. Socinski, Xiaofei F. Wang, -1

机译：晚期IIIB / IV期非小细胞肺癌初始铂类联合化疗后的维持舒尼替尼：一项随机双盲安慰剂对照的III期研究—CALGB 30607（联盟）
7. 378MO EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50 [O] . A. Sezer, S. Kilickap, M. Gümüş, 2020

机译：378Mo Empower-Lung 1：III期第一线（1L）CeMiplimab单药治疗与先进的非小细胞肺癌（NSCLC）中的铂 - 双胞胎化疗（Chemo），具有编程的细胞死亡 - 配体1（PD-L1）≥50％

LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

著录项

相似文献

相关主题

期刊订阅